VREX · Varex Imaging Corporation · Stock research

Current Thesis

On 2026-08-10 Varex signed a definitive merger agreement with Teledyne Technologies at $18.90 per share in cash, a transaction valued at roughly $1.1 billion including net debt and equity awards. Every fundamental storyline in this name — X-ray tube and detector supply, the Medical/Industrial mix, the FY26 margin recovery — has been collapsed into one number and one question: does the deal close, and when. The 2026-08-14 close of $18.49 sits about $0.41 under the cash consideration, for a transaction the parties guided to complete in early calendar 2027 with a 2027-05-10 outside date. That is a long carry for a thin gap, with the downside anchored not at a moving average but at the undisturbed price.

Life-cycle: SATURATED. The re-rate happened in a single session on 2026-08-10; sell-side reset to neutral within 24 hours (Sidoti to Neutral with a $19 target on 2026-08-10, Oppenheimer to Perform on 2026-08-11); by 2026-08-14 the name appeared in generic weekly M&A roundups alongside MarineMax and Accelerant. Coverage is mainstream, the price is pinned within ~2% of a contractual ceiling, and no buyer pays above $18.90 without a competing proposal.

Bullish and bearish views on Varex Imaging Corporation

The model's bull view on Varex Imaging Corporation (VREX), in brief: Fixed consideration, no financing condition. The bear view: Upside is contractually capped. Absent a superior proposal, $18.90 is the terminal value. The 2026-08-14 close of $18.49 leaves ~$0.41 of gross gap against a closing guided for "early calendar 2027" and an outside date of 2027-05-10. Asymmetric break risk. The 52.3% premium… Both cases follow in full.

Bull Case

• Fixed consideration, no financing condition. $18.90/share cash, both boards unanimously approving on 2026-08-10; Teledyne indicated funding from its existing credit facility, removing the financing leg from the risk stack.
• Operating trend does not support a material-adverse-effect argument. Fiscal Q3 (quarter ended 2026-07-03): revenue $210.5M vs $203.0M a year earlier, GAAP net income of $15.7M against an $89.1M loss in the year-ago quarter, gross margin 36.4%. Adjusted EPS came in at $0.31 versus the $0.21 consensus (Benzinga correction, 2026-08-10).
• Strategic buyer at a strategic multiple. InsideArbitrage put the price at 10.76x EBITDA and a 52.3% premium to the prior close (2026-08-10) — an industrial acquirer absorbing a component supplier, not a sponsor stretching for leverage. Inference, not a disclosed fact: buyer-remorse risk in that structure is lower than in a financed LBO.
• The refinancing overhang was cleared before signing. The 10-Q for the quarter ended 2026-07-03 shows a new $350.0M term loan and $100.0M revolver replacing the remaining $368.0M of senior secured notes, with a $9.4M loss on extinguishment — no maturity wall to negotiate across a multi-quarter regulatory review.
• A modest break fee. $25.3M against a ~$1.1B transaction value is a low barrier should a second bidder emerge; that is optionality, not a base case, and nothing in the record to date indicates a competing party.

Bear Case

• Upside is contractually capped. Absent a superior proposal, $18.90 is the terminal value. The 2026-08-14 close of $18.49 leaves ~$0.41 of gross gap against a closing guided for "early calendar 2027" and an outside date of 2027-05-10.
• Asymmetric break risk. The 52.3% premium cited on 2026-08-10 implies an undisturbed level in the low $12s. A termination would reprice the equity toward that, against a gross gap of about 2%.
• Regulatory is the live variable. Conditions include HSR clearance, foreign merger-control clearances, absence of legal restraints, no material adverse effect, and adoption by a majority of shares outstanding. The foreign-clearance list is the item to read in the proxy — Varex sells detectors and tubes to imaging OEMs globally, and an Asian or European review is the plausible source of a timeline extension.
• Standalone cash generation is soft. Nine-month FY26 operating cash flow of $3.4M against $33.8M a year earlier, cash down to $99.2M from $145.0M, inventories up to $347.1M from $299.4M (10-Q, quarter ended 2026-07-03). Revenue also missed on the print: $210.5M vs $213.94M consensus. A deal-break returns a shareholder to that company.
• No fundamental bid left. With the highest published target at $19 (Sidoti, 2026-08-10) — effectively the deal price — no analyst is arguing for standalone value above the consideration.

Setup & Price Structure

• 2026-08-14 close $18.49, 0.5% under the $18.58 52-week high; three-month return +91.4%. Both figures are artifacts of the announcement gap rather than evidence of accumulating trend demand.
• RSI(14) at 94.5 measures a one-day step function. In a signed cash deal the oscillator carries no information about the next move;
• The tradable structure is the gap, not the chart. Compression toward $18.90 accompanies clearance milestones (HSR expiry, proxy mailing, vote); widening accompanies regulatory friction. There is no base to break out of and no trend to extend.
• Ceiling test: sustained closes above $18.90 would signal the market handicapping a topping bid. That is observable and gradeable; nothing in the record through 2026-08-14 supports it.
• Downside marker: a slide through $17.50 puts the gross gap beyond ~7%, a level more consistent with doubt about completion than with the discount rate on five months of time.
• Positioning observables, stated as observables: sell-side ratings collapsed to Neutral/Perform within one session of announcement; the highest target ($19) sits ~$0.10 above the consideration; the marginal holder rotates from fundamental to event-driven, which will show up in the next 13F/13G cycle. No insider transactions appear in the filing record supplied through 2026-08-14.

Catalyst Calendar (next 30 days)

• ~2026-08 late (est.) — HSR filing by the parties; the initial 30-day waiting period runs from filing. Neither the filing date nor an expiry has been disclosed.
• ~2026-09 (est.) — Preliminary merger proxy (PREM14A). This document fixes the special-meeting timetable and, more usefully, lists every required foreign clearance and the background-of-the-merger section (whether other bidders were contacted).
• ~2026-11 (est.) — Fiscal Q4/FY26 results. Under a pending merger the company may forgo guidance and a call; the Q3 10-Q already carried no forward guidance.
• 2027-05-10 — outside date under the merger agreement.

Elapsed catalysts

• No confirmed dated catalyst falls inside the 30-day window as of 2026-08-14. The special-meeting date follows the definitive proxy and has not been set. (passed 1d ago)
• Early 2027 (company guidance, 2026-08-10) — targeted closing. (passed 5d ago)

What Would Change Our Mind

The structure that can break here is the merger agreement, not a price pattern. The read turns negative on any of: an 8-K disclosing an antitrust second request or a foreign regulator opening an in-depth review; a proxy that pushes the special meeting materially later than the early-2027 closing guidance; a proxy background section showing a single-bidder process with no market check; or outright termination, which pays Teledyne nothing and returns the equity to a company that generated $3.4M of operating cash flow in nine months. Expressed as a gradeable level, a daily close below $17.50 — a gross gap wider than about 7% to the $18.90 cash price — indicates completion risk being priced rather than time value, and that is the point at which the arithmetic of a 2% gap against low-$12s break risk stops holding. The read changes in the other direction on sustained closes above $18.90, which would price a competing bid rather than the signed one. And if the 2027-05-10 outside date arrives with the deal unconsummated and unextended, the thesis is finished regardless of where price sits.

Correlation Notes

• Since 2026-08-10 the daily correlation to med-tech and industrial-instrument peers should approach zero; the price is a function of days-to-close and completion probability. What now moves it is antitrust news flow, not imaging capex or a peer's print.
• Teledyne's own operating performance is a weak driver: with no financing condition and funding from an existing credit facility, TDY credit spreads are not the transmission channel. Buyer distress would matter only through a walk-and-pay-damages scenario, which the agreement does not contemplate cheaply.
• Read-through to the sector runs through the multiple, not the tape: 10.76x EBITDA and a 52.3% premium (InsideArbitrage, 2026-08-10) set a public comparison point for other sub-scale medical and industrial component suppliers.
• The name now correlates with the merger-arb complex generally — spread widening across pending deals during a risk-off week, or a shift in US antitrust stance, would move it more than anything Varex reports.